Researchers developed CAR T cells directed against one of the targets, FOLR1, and demonstrated their pre-clinical efficacy against CBFA2T3-GLIS2 acute megakaryoblastic leukemia using in vitro and xenograft models.
[Journal of Clinical Investigation]
